These Form 3 filings confirm substantial insider ownership and alignment. Monitor for any subsequent Form 4 filings (transactions) or an S-1 registration statement for the IPO, which would trigger automatic conversion of the Series A Preferred and provide a clearer picture of the post-IPO capital structure.
Price Chart
Executive Summary
Three initial beneficial ownership filings (Form 3) were filed on August 5, 2026, by Erez Chimovits (OrbiMed Advisors), Travis Murdoch (CEO/President), and Jason V. Coloma (director) for Braveheart Bio, Inc. (BRVE). These filings disclose significant insider holdings: Chimovits reports 1,102,739 common shares and 9,132,420 shares underlying convertible Series A Preferred via OrbiMed Private Investments IX, LP; Murdoch reports 3,338,175 common shares via the Murdoch Family Trust, 1,027,396 shares in each of two irrevocable gift trusts, and 2,857,337 shares directly; Coloma reports 93,607 shares in each of two family trusts and 913,242 shares via Westport Meridian Capital LP. These are routine initial ownership disclosures required upon becoming an insider, not transactions, and indicate substantial insider alignment with shareholders.
Key Facts
- Erez Chimovits (OrbiMed) reports beneficial ownership of 1,102,739 common shares and 9,132,420 common shares issuable upon conversion of Series A Preferred Stock via OrbiMed Private Investments IX, LP.
- Travis Murdoch (CEO/President) reports beneficial ownership of 3,338,175 common shares via the Murdoch Family Trust, 1,027,396 shares in each of two irrevocable gift trusts, and 2,857,337 shares directly.
- Jason V. Coloma (director) reports beneficial ownership of 93,607 common shares in each of two family trusts and 913,242 common shares via Westport Meridian Capital LP.
- Series A Preferred Stock is convertible into Common Stock on a one-for-4.38 basis and automatically converts upon closing of the issuer's initial public offering.
- All three filings are initial statements of beneficial ownership (Form 3), not transactions, filed on August 5, 2026.
- Each reporting person disclaims beneficial ownership except for pecuniary interest, and each has granted a limited power of attorney to Natalie Dement and James Paul Rickey for future Section 16 filings.
Financial Impact
No financial impact from these filings; they are initial ownership disclosures. The disclosed holdings represent significant insider ownership, with OrbiMed's convertible preferred position alone representing over 9 million common shares upon conversion.
Risk Factors
- No material risks identified from these routine initial ownership filings.
- The company is pre-IPO; the automatic conversion of Series A Preferred upon IPO closing introduces potential dilution to new public investors, though the conversion ratio (1:4.38) is already disclosed.
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (BRVE) — Batch item 1 | 0001470831-26-000775 |
| Document: 0001470831-26-000775-index-headers.html | 0001470831-26-000774 |
| Document: 0001470831-26-000775-index.html | 0001470831-26-000771 |
| Document: 0001470831-26-000775.txt | 0001470831-26-000775 |
| 3 Filing (BRVE) — Batch item 5 | 0001470831-26-000774 |
| Document: 0001470831-26-000774-index-headers.html | 0001470831-26-000775 |
| Document: 0001470831-26-000774-index.html | 0001470831-26-000775 |
| Document: 0001470831-26-000774.txt | 0001470831-26-000775 |
| 3 Filing (BRVE) — Batch item 9 | 0001470831-26-000771 |
| Document: 0001470831-26-000771-index-headers.html | 0001470831-26-000775 |
| Document: 0001470831-26-000771-index.html | 0001470831-26-000775 |
| Document: 0001470831-26-000771.txt | 0001470831-26-000775 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 3 | $27.66 $26.71 | ▼ −3.43% | ▼ −1.46% | $21.82 (−21.11%) |
Aug 11, 2026 10w ago | Insider Cluster | $26.15 $27.25 | ▲ +4.21% | ▲ +6.10% | $21.82 (−16.56%) |
Aug 11, 2026 10w ago | Insider Cluster | $26.15 $27.25 | ▲ +4.21% | ▲ +6.10% | $21.82 (−16.56%) |
Aug 7, 2026 11w ago | Insider Cluster | $27.53 $29.41 | ▲ +6.83% | ▲ +7.74% | $21.82 (−20.74%) |
Aug 7, 2026 11w ago | Insider Cluster | $27.53 $29.41 | ▲ +6.83% | ▲ +7.74% | $21.82 (−20.74%) |
Aug 5, 2026 11w ago | Press Release | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.82 (−26.78%) |
Aug 5, 2026 11w ago | 3 | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.82 (−26.78%) |
Aug 5, 2026 11w ago | 3 | $29.80 $26.27 | ▼ −11.85% | ▼ −12.45% | $21.82 (−26.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers